The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$2.07M | 9 mos ago

About Armonica Technologies

Armonica Technologies is developing a DNA sequencing platform that will sequence a complete human genome in minutes.

Armonica Technologies Headquarter Location

5901 Indian School Rd NE Suite 117

Albuquerque, New Mexico, 87110,

United States

(505) 336-0858

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Armonica Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Armonica Technologies is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Armonica Technologies Patents

Armonica Technologies has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • DNA sequencing
patents chart

Application Date

Grant Date


Related Topics



Molecular biology, Genetics, DNA, Biotechnology, DNA sequencing


Application Date


Grant Date


Related Topics

Molecular biology, Genetics, DNA, Biotechnology, DNA sequencing



Latest Armonica Technologies News

Armonica Technologies完成B轮融资

Oct 19, 2021

Armonica Technologies完成B轮融资 本文共1080个字,阅读需3分钟 Armonica Technologies, Inc., a biotechnology company developing a high throughput, direct long-read DNA sequencing technology, announced that it has raised $2M in new funding. The funding will support further feasibility demonstration of company's sequencing technology.Akira Hiruma, President and CEO of Hamamatsu Photonics K.K., said, "At Hamamatsu, we are excited about our investment in Armonica, and their novel nanopore optical spectroscopy with its potential of new genetic sequencing methods to areas such as precision medicine. By investing in Armonica's technology we hope to speed the development of new and more effective treatments to some of the world's most devastating diseases. "The Company's CEO, Victor Esch, Ph.D. stated, "There continues to be an unmet clinical need for fast, high throughput long-read sequencing of native DNA, with an efficient workflow, that accurately identifies variants and epigenetics to enable clinical applications. We are very excited about the progress the company has made in key areas of our technology, including the measurement of single nucleotide spectra. "Armonica's proprietary platform solves the fundamental challenges involved with traditional sequencing methodology, such as low speed and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single bases optically, without the need for library prep or adding biological constructs. Armonica's optical readout technology is label free, has massive parallel capabilities, and can measure all epigenetic modifications directly. This unique approach to long-read sequencing will provide clinicians and researchers with a powerful tool that can detect previously unseen nuances and provide more accurate identification of genome variations and abnormalities.About Armonica TechnologiesArmonica Technologies is an Albuquerque, NM based biotechnology company focused on developing its proprietary long-read DNA sequencing technology. Armonica's technology, optical nanopore sequencing, uses proprietary nanochannels to deliver long, single DNA molecules through nanopores, where characteristic optical signatures are read. Armonica's approach will lead to faster, more thorough and more accurate genomic analysis than is currently available, without the need for extensive workflow and reagents. The Company's innovative platform will enable clinicians to develop novel diagnostic tests that are based on complex variants including epigenetic modifications, and life science researchers to be more efficient and productive in their research and discovery capabilities.View original content: Armonica Technologies, Inc 新墨西哥州阿尔伯克基2021年10月18日电/PRNewswire/--Armonica Technologies,Inc.是一家开发高通量、直接长读DNA测序技术的生物技术公司,该公司宣布已筹集200万美元的新资金。融资包括滨松光子学公司以及目前的投资者杨木科技基金、太阳山资本和电车威风险投资伙伴。这笔资金将支持公司测序技术的进一步可行性论证。Hamamatsu Photonics K.K.的总裁兼首席执行官Akira Hiruma说:“在Hamamatsu,我们对我们在Armonica的投资感到兴奋,他们新颖的纳米孔光学光谱技术及其在精准医学等领域的新基因测序方法的潜力。通过投资Armonica的技术,我们希望加快开发新的、更有效的治疗世界上一些最具破坏性的疾病的方法。”该公司首席执行官维克多·埃施博士他说,“对于快速、高通量的本地DNA长读测序,以及高效的工作流程,仍有未满足的临床需求,该工作流程可以准确识别变异体和表观遗传学,以实现临床应用。我们对公司在关键技术领域取得的进展感到非常兴奋,包括单核苷酸光谱测量。”Armonica的专有平台解决了传统测序方法学的基本挑战,如速度低和精度有限,通过自然控制核酸通过纳米通道运输的速度和光学读取单碱基,而不需要库准备或添加生物构建。Armonica的光学读出技术是无标签的,具有大规模的并行能力,可以直接测量所有表观遗传修饰。这种独特的长读测序方法将为临床医生和研究人员提供一个强大的工具,可以检测以前看不到的细微差别,并提供更准确的基因组变异和异常的识别。关于Armonica TechnologiesArmonica Technologies是一家总部位于新墨西哥州阿尔伯克基的生物技术公司,专注于开发其专有的长读DNA测序技术。Armonica的技术,光学纳米孔测序,使用专有的纳米通道,通过纳米孔传递长的,单一的DNA分子,在那里特征光学签名被读取。Armonica的方法将导致比目前更快、更彻底和更准确的基因组分析,而不需要大量的工作流程和试剂。该公司的创新平台将使临床医生能够开发基于包括表观遗传修饰在内的复杂变体的新型诊断测试,并使生命科学研究人员在研究和发现能力方面更加高效和富有成效。查看原文内容:来源Armonica Technologies,Inc 以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

  • When was Armonica Technologies founded?

    Armonica Technologies was founded in 2015.

  • Where is Armonica Technologies's headquarters?

    Armonica Technologies's headquarters is located at 5901 Indian School Rd NE, Albuquerque.

  • What is Armonica Technologies's latest funding round?

    Armonica Technologies's latest funding round is Series B.

  • How much did Armonica Technologies raise?

    Armonica Technologies raised a total of $2.83M.

  • Who are the investors of Armonica Technologies?

    Investors of Armonica Technologies include Sun Mountain Capital, Cottonwood Technology Fund, Hamamatsu Photonics Corporate Venture Capital, Tramway Venture Partners, National Human Genome Research Institute and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.